Renaissance Technologies
AQST icon

Renaissance Technologies’s Aquestive Therapeutics AQST Stock Holding History

Renaissance Technologies’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Buy
+416,248
New +$1.75M ﹤0.01% 2048
2026
Q1 		– Sell
-414,400
Closed -$2.68M – 3239
2025
Q4 		$2.68M Buy
414,400
+327,400
+376% +$2.04M ﹤0.01% 1688
2025
Q3 		$486K Buy
+87,000
New +$376K ﹤0.01% 2808
2025
Q1 		– Sell
-95,400
Closed -$340K – 3441
2024
Q4 		$340K Buy
95,400
+66,800
+234% +$308K ﹤0.01% 2994
2024
Q3 		$142K Sell
28,600
-467,600
-94% -$1.82M ﹤0.01% 3191
2024
Q2 		$1.29M Sell
496,200
-879,600
-64% -$2.94M ﹤0.01% 2174
2024
Q1 		$5.86M Buy
1,375,800
+104,300
+8% +$347K 0.01% 1314
2023
Q4 		$2.57M Buy
1,271,500
+142,311
+13% +$251K ﹤0.01% 1796
2023
Q3 		$1.73M Sell
1,129,189
-101,007
-8% -$174K ﹤0.01% 1950
2023
Q2 		$2.03M Buy
1,230,196
+711,396
+137% +$1.29M ﹤0.01% 1988
2023
Q1 		$591K Buy
518,800
+56,063
+12% +$48.6K ﹤0.01% 2793
2022
Q4 		$417K Sell
462,737
-438,063
-49% -$411K ﹤0.01% 3051
2022
Q3 		$1.05M Sell
900,800
-325,600
-27% -$368K ﹤0.01% 2466
2022
Q2 		$785K Buy
1,226,400
+1,192,100
+3,476% +$1.59M ﹤0.01% 2866
2022
Q1 		$90K Buy
34,300
+23,043
+205% +$67.3K ﹤0.01% 3812
2021
Q4 		$44K Sell
11,257
-178,412
-94% -$895K ﹤0.01% 3793
2021
Q3 		$827K Sell
189,669
-55,779
-23% -$219K ﹤0.01% 2651
2021
Q2 		$974K Buy
+245,448
New +$980K ﹤0.01% 2682
2021
Q1 		– Sell
-271,800
Closed -$1.45M – 3291
2020
Q4 		$1.45M Buy
+271,800
New +$1.63M ﹤0.01% 2306
2020
Q2 		– Sell
-294,051
Closed -$644K – 3418
2020
Q1 		$644K Buy
294,051
+215,051
+272% +$817K ﹤0.01% 2640
2019
Q4 		$460K Buy
+79,000
New +$411K ﹤0.01% 2936

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies's AQST Position: Q2 2026 in Review

Renaissance Technologies opened a new position in Aquestive Therapeutics (AQST) in Q2 2026: 416,248 shares worth $1.73M. The stake represents ﹤0.01% of the portfolio and ranks #2048 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in AQST as recently as Q4 2025.

Renaissance Technologies first reported a position in AQST in Q4 2019 and has held it in 21 quarters since. The position peaked at $5.86M in Q1 2024. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Renaissance Technologies held 416,248 shares of Aquestive Therapeutics worth $1.73M as of Q2 2026.
  • Aquestive Therapeutics was a new Renaissance Technologies position in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2048 holding.
  • Renaissance Technologies first reported a position in Aquestive Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • Renaissance Technologies's Aquestive Therapeutics position peaked at $5.86M in Q1 2024.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.